PT-141 (Bremelanotide): MC4-R Mechanism and FDA Approval
Analysis of PT-141: melanocortin analogue, MC4-R receptor agonist, FDA approval as Vyleesi® for FSIAD and differences compared to PDE-5 inhibitors.
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Mechanism of Action
PT-141 (Bremelanotide) is a non-selective agonist of melanocortin receptors MC3R and MC4R, acting via the CNS. Unlike PDE5 inhibitors that act peripherally, studies demonstrate PT-141 activates dopaminergic pathways in the hypothalamus involved in motivation and sexual desire, independent of genital vascular response.
Data based on available scientific literature. Protocol individualization depends on qualified professional assessment.
Applications Described in the Literature
- ✓Clinical trials in Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women — FDA approved as Vyleesi
- ✓Exploratory studies in erectile dysfunction resistant to PDE5 inhibitors
- ✓Research in central vs peripheral sexual motivation
- ✓Investigations in antidepressant (SSRI)-induced sexual desire loss
Relevant Studies
Bremelanotide for hypoactive sexual desire disorder in premenopausal women (FDA approval studies)
2018 · PMID: 30256986
Melanocortin receptors as targets for the treatment of sexual dysfunction
2009 · PMID: 19014744
PT-141: A melanocortin agonist for the treatment of sexual dysfunction
2004 · PMID: 14997030
Premium
✓ DesbloqueadoProtocols Described in the Literature
Vyleesi (PT-141) was approved in subcutaneous formulation for on-demand use, 45 minutes to 1 hour before sexual activity. Clinical trials evaluated efficacy in number of satisfying sexual events and reduction of distress associated with HSDD. Exploratory studies in erectile dysfunction used intranasal formulations in original research.
Dose Ranges Observed in Studies
- ◆FDA-approved dose for HSDD: 1.75 mg subcutaneous on-demand
- ◆Original studies used ranges of 1–2 mg intranasal and subcutaneous
- ◆Maximum of 1 use per 24 hours and 8 uses per month described in safety studies
- ◆Erectile dysfunction research: ranges of 4–20 mg intranasal in exploratory investigations
Effects Timeline (Literature)
Studies demonstrate onset of effect in 45–60 minutes after subcutaneous administration. Duration of effect of 6–12 hours documented in pharmacodynamic studies. Efficacy studies evaluated 24 weeks of on-demand use with maintained response.
Documented Associations
- ↗Kisspeptin: plausibility of complementary action — kisspeptin acts upstream (GnRH axis), PT-141 acts centrally via melanocortins
- ↗PDE5 inhibitors (sildenafil, tadalafil): complementary mechanism, central vs peripheral action
- ↗Testosterone: studies in men with combined libido and testosterone deficit
Monitoring Described in Studies
- ⊕Blood pressure: transient ~6 mmHg drop documented in clinical studies
- ⊕Heart rate: slight elevation described in safety studies
- ⊕Nausea: most prevalent adverse effect (39%) in Vyleesi trials
- ⊕Facial erythema and flushing: documented in ~20% of participants
Clinical Observations from Studies
- ℹOnly FDA-approved central-acting female sexual dysfunction treatment (along with flibanserin)
- ℹContraindication to combined use with PDE5 inhibitors in clinical trials
- ℹFocal hyperpigmentation: described in long-term regular use studies
- ℹCentral mechanism fundamentally distinguishes it from peripheral vasodilators
All information above is exclusively educational, based on scientific literature. It does not constitute medical prescription. Individualization of any protocol requires evaluation by a qualified healthcare professional.
Frequently Asked Questions
What is PT-141 (Bremelanotide)?▼
PT-141 is a synthetic analogue of α-MSH (melanocyte-stimulating hormone), an MC4-R receptor agonist in the central nervous system. FDA-approved in 2019 as Vyleesi® for treatment of FSIAD in premenopausal women.
⚠️ Medical Disclaimer: The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.